Comparison of incidence rates pre-13-valent pneumococcal conjugate vaccine (PCV13)# and post-PCV13¶ introduction
| Overall incidence+ | IRR (95%CI) | p-value | ||
| Pre-PCV13 | Post-PCV13 | |||
| CAP | 90.7 (83.0–99.0) | 76.7 (72.6–81.0) | 0.85 (0.76–0.94) | 0.001 |
| Pneumococcal CAP | 35.1 (30.4–40.4) | 18.3 (16.3–20.5) | 0.52 (0.44–0.62) | <0.001 |
| PCV7 CAP | 11.1 (8.5–14.2) | 1.4 (0.9–2.1) | 0.12 (0.08–0.20) | <0.001 |
| Additional PCV13 CAP | 10.6 (8.0–13.6) | 7.4 (6.2–8.8) | 0.70 (0.51–0.96) | 0.024 |
| Other CAP | 4.3 (2.8–6.4) | 2.9 (2.1–3.8) | 0.67 (0.41–1.09) | 0.105 |
Data are presented as incidence rates (interquartile range), unless otherwise stated. IRR: incidence rate ratio; CAP: community-acquired pneumonia; PCV7 CAP: CAP due to serotypes included in the PCV7 vaccine; additional PCV13 CAP: CAP due to serotypes included in the PCV13 vaccine; other CAP: CAP due to “other” serotypes. #: years 2008–2009; ¶: years 2010–2013; +: per 100 000 population. Bold indicates statistically significant.